Latest by Canadian AIDS Treatment Information Exchange
Chronic HIV infection is associated with relatively high levels of inflammation and a growing body of evidence suggests that inflammation may increase the risk for a range of health problems.
New research assesses the impact of chronic inflammation on major clinical events -- heart attack, stroke, cancer, other serious complications, and the risk of death.
A study of people with HIV and hepatitis C co-infection finds that limited access to food is associated with higher levels of HIV in the blood and 10% fewer CD4+ immune cells.
As one of the few global health threats with easy solutions, why aren't we seeing an impact on the viral hepatitis epidemic?
By 2035, three-quarters of HIV-positive people in Italy and the U.S. will be over the age of 50. Researchers are calling for "multidisciplinary patient management" and geriatric medicine training for doctors who care for people living with HIV.
An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.
Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.
Canadian researchers sought to find out where patients who dropped out of HIV care went to receive their non-HIV care, as these could potentially be places where they may be helped to re-enter HIV care.
Sixty percent of HIV-positive people in New York City who died between 2007 and 2013 had not been virally suppressed through treatment.
Researchers found that, although HIV testing and treatment cost money, over the long term their impact on health resulted in savings because fewer people became infected with HIV.